What Has Been the Progress and Growth of the Primary Biliary Cholangitis Market in Recent Years?
The primary biliary cholangitis market has seen considerable growth due to a variety of factors.
• The market size for primary biliary cholangitis has significantly expanded in the past few years. The growth is projected to continue from $0.98 billion in 2024 to $1.09 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%.
This expansion during the historic period is credited to enhanced disease recognition, escalated worldwide medical care spending, strategic alliances in the medical field, emphasis on patient representation, and governmental efforts towards liver health.
How Does the Forecast Look for the Primary Biliary Cholangitis Market?
The primary biliary cholangitis market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, it is predicted that the primary biliary cholangitis market will experience robust growth, expanding to $1.6 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%.
This growth during the predicted period is likely due to several factors such as the expansion of biomarker research, worldwide initiatives in managing rare diseases, increased partnerships in clinical trials, patient-oriented healthcare methodologies, and an escalating need for liver transplants. Significant trends for the forecast period entail advancement in biomarker research, an increased focus on non-invasive diagnostic methods, research emphasis on immunomodulatory therapies, the incorporation of artificial intelligence (ai), patient-reported results in clinical trials, the application of telemedicine for patient management, a focus on combination therapies, and upcoming therapies targeting fibrosis.
What Are The Leading Drivers Of Growth In The Primary Biliary Cholangitis Market?
The primary biliary cholangitis market is poised for growth, spurred on by the rising prevalence of smoking. This act entails the inhalation and exhalation of smoke from burning tobacco or other substances. It's recognized that smoking is a risk factor for liver diseases, inclusive of PBC, and a rise in smoking will result in a greater number of people seeking healthcare for liver-related conditions. For example, government agency, Statistics Canada, reported that cigarette production in July 2023 witnessed an increase by 2.2% from June 2023, and there was a 2.6% uptick in cigarette sales in the same month, reaching 1.4 billion units. Therefore, the primary biliary cholangitis market is set to benefit from increasing smoking rates.
Primary Biliary Cholangitis Market Driver: Increase in Liver Cancer Cases Boosts Growth in Primary Biliary Cholangitis Market
How Are The Segments Defined Within The Global Primary Biliary Cholangitis Market?
The primary biliary cholangitis market covered in this report is segmented –
1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant
Pre-Book The Primary Biliary Cholangitis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Primary Biliary Cholangitis Market?
Organizations operating within the primary biliary cholangitis market are aiming to carve out an exclusive niche for themselves by creating specialized and novel treatments. These include a mix of obeticholic acid (OCA) and bezafibrates, designated as orphan drugs, aimed specifically at tackling primary biliary cholangitis (PBC). The objective is to offer a comprehensive and superior method of managing PBC, increasing the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical entity from the US, was granted the status of an orphan drug by the FDA in May 2023. This was for the combined use of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible means of treating primary biliary cholangitis (PBC), a degenerative liver disease. The US has approved the use of obeticholic acid (known in the market as Ocaliva) for PBC treatment.
Who Are the Key Players In The Primary Biliary Cholangitis Market?
Major companies operating in the primary biliary cholangitis market report are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck And Co. Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals
• Dr. Reddy’s Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• CureVac N.V.
• Sangamo Therapeutics Inc.
• Calliditas Therapeutics AB
• NGM Biopharmaceuticals Inc.
• Bluebird Bio Inc.
• Intellia Therapeutics Inc.
• Albireo Pharma Inc.
• TARGET PharmaSolutions Inc.
• Genfit S.A.
• Editas Medicine Inc.
• CymaBay Therapeutics Inc.
• Ascletis Pharma Inc.
What Is The Most Dominant Region In The Primary Biliary Cholangitis Market?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
